Profile
Richard Schoenfeld is Vice President of Operations for PharmAthene, Inc. He joined PharmAthene in October 2005.
He was Vice President of Supply Chain Management for EMD Pharmaceuticals and Senior Vice President of Engineering and Technology Development for Genzyme.
Mr. Schoenfeld held various positions at Endotronics and Monsanto.
He had 30 years of experience in developing and manufacturing proteins.
Mr. Schoenfeld received an Advanced Graduate Certificate in Business Ethics from Bentley College.
He received an MS and a PhD in Bioengineering from the Polytechnic Institute of Brooklyn, a BS in Chemical Engineering from Northeastern University and an MBA from St. Louis University.
Former positions of Richard Schoenfeld
| Companies | Position | End |
|---|---|---|
PharmAthene, Inc. /Old/
 PharmAthene, Inc. /Old/ BiotechnologyHealth Technology PharmAthene, Inc. develops biotherapeutics to address biological pathogens and chemicals. It provides clinical and preclinical development for Bacillus anthracis a therapeutic anti-toxin for treatment of symptomatic patients infected with anthrax monoclonal. The company was founded in 2001 and is located in Annapolis, MD. | Chief Operating Officer | 2007-08-08 |
PharmAthene, Inc.
 PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | Corporate Officer/Principal | - |
Training of Richard Schoenfeld
| Northeastern University | Undergraduate Degree |
| St. Louis University | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
PharmAthene, Inc. /Old/
PharmAthene, Inc. /Old/ BiotechnologyHealth Technology PharmAthene, Inc. develops biotherapeutics to address biological pathogens and chemicals. It provides clinical and preclinical development for Bacillus anthracis a therapeutic anti-toxin for treatment of symptomatic patients infected with anthrax monoclonal. The company was founded in 2001 and is located in Annapolis, MD. | Health Technology |
| Polytechnic University | Consumer Services |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | Health Technology |
- Stock Market
- Insiders
- Richard Schoenfeld
